<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212182</url>
  </required_header>
  <id_info>
    <org_study_id>GIRH-HFNC8306</org_study_id>
    <nct_id>NCT04212182</nct_id>
  </id_info>
  <brief_title>The Physiological Effect of High Flow Oxygen Therapy</brief_title>
  <official_title>The Physiological Effect of High Flow Oxygen Therapy on Acute Exacerbation of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although non-invasive positive pressure ventilation (NPPV) shows the good curative effect of
      treating the patients with acute exacerbation of chronic obstructive pulmonary disease
      (AECOPD), some patients do not tolerate NPPV or do not benefit from it. High-flow nasal
      cannula (HFNC) is well tolerated and may be used to patients with AECOPD who are intolerant
      to NPPV treatment. This study is to evaluate the physiological effect of HFNC and compare it
      with NPPV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural respiratory drive</measure>
    <time_frame>30 minutes</time_frame>
    <description>Neural respiratory drive is calculated by diaphragm electromyogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Work of breathing</measure>
    <time_frame>30 minutes</time_frame>
    <description>Work of breathing is calculated by the transdiaphragmatic pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous CO2</measure>
    <time_frame>30 minutes</time_frame>
    <description>Transcutaneous CO2 is a non-invasive method estimated the partial pressure of arterial blood CO2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>High-flow Nasal Cannula</condition>
  <condition>Non-invasive Positive Pressure Ventilation</condition>
  <condition>Acute Exacerbation of Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>HFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AECOPD patients receive ventilation support via HFNC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPPV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AECOPD patients receive ventilation support via NPPV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFNC</intervention_name>
    <description>HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.</description>
    <arm_group_label>HFNC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NPPV</intervention_name>
    <description>NPPV is the standard therapy for ventilatory failure in AECOPD.</description>
    <arm_group_label>NPPV group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AECOPD patients with acute hypercapnic respiratory failure

        Exclusion Criteria:

          -  other lung/pleural diseases or thoracic deformity

          -  severe heart failure (New York Heart Association class IV), severe dysrhythmia

          -  unstable angina, or malignant comorbidity

          -  obesity (BMI ≥ 35 kg/m²)

          -  severe obstructive sleep apnea syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongchang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lili Guan, PhD</last_name>
    <phone>+8613422288665</phone>
    <email>dr_nickguan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University.</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Guan, PhD</last_name>
      <phone>+8613422288665</phone>
      <email>dr_nickguan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Rongchang Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

